18 April 2018 - - UK-based biopharmaceutical company PhoreMost has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R and D centre of Tokyo, Japan-based pharmaceutical company Daiichi Sankyo Company, Ltd., the company said.
The goal of the collaboration will be to deliver novel drug targets that can serve as starting points for new drug discovery initiatives led by Plexxikon.
Under the agreement, PhoreMost will apply Siteseeker, its next-generation phenotypic screening platform, toward key cancer-driving cellular pathways, and draw upon expertise in signal transduction from Dr. Simon Cook at the Babraham Institute (Cambridge, UK).
Cook said: "I am thrilled to be working together with both PhoreMost and Plexxikon. This is a great example of partners with complementary skill-sets coming together to identify and validate elusive new drug targets."
PhoreMost is dedicated to drugging 'undruggable' disease targets.
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets.
Its research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology.